JAKARTA – Government Spokesperson for Handling Covid-19 Wiku Adisasmito said that the Sinopharm vaccine has received emergency use authorization (EUA) in more than 27 countries. Including Indonesia since April 2021.
“And the emergency use listing or EUL from WHO on May 7, 2021,” he said in his press conference, Friday (28/5//2021).
He said the phase 3 clinical study was conducted on more than 42,000 subjects in the United Arab Emirates and several countries. From these clinical trials, the efficacy rate is quite high.
Also read: Covid-19 Cases Soared After Lebaran, Task Force: Consequences to Face
“Shows the efficacy of the COVID-19 vaccine from Sinopharm’s production of 78.02%. Then the results of measuring the immunogenicity of the use of this vaccine show that the formation of antibodies is high in adults and the elderly,” he said.
Even so, to determine its effectiveness or ability in reducing the risk of transmission in the community, further studies are still needed. As is known, the Sinopharm vaccine itself is used by the government in the mutual cooperation vaccination program.
Also read: Indonesia Hasn’t Looked At Covid-19 Vaccines For Children
“And it needs to be a reminder for us all that vaccination alone is not enough to provide prime protection in preventing transmission. Because in principle, all types of Covid control efforts with complementarity cannot stand alone and run at the same time,” he concluded.
(qlh)
–
